Propanc Biopharma Inc Dossier - Source-backed chat

Propanc Biopharma Inc

PPCBNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $3.2M

Enterprise Value $3.2M

Shares Outstanding 2.3M diluted

Next Earnings Date31 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Propanc Biopharma is transitioning into a clinical-stage oncology company, preparing to advance its lead proenzyme asset, PRP, into a Phase 1b first-in-human trial in late 2026. While preclinical data shows promising tumor inhibition and the company has secured a flexible private placement facility of up to $100 million, its extremely low cash reserves ($443,702 as of March 31, 2026) and heavy reliance on dilutive financing present significant risks. The recent 1-for-25 reverse stock split highlights ongoing struggles to maintain Nasdaq listing compliance. A 'Hold' recommendation is advised until clinical trial enrollment begins and the financial runway stabilizes.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The bear case is triggered by delays in the GMP manufacturing schedule or regulatory hurdles with the Australian CTA, pushing the Phase 1b trial into late 2027. Severe dilution from drawing down the Series C facility to cover high operational burn rates could crush the share price. Additionally, if the stock fails to maintain the $1.00 minimum bid price despite the reverse split, a delisting from Nasdaq to the OTC market would severely impair liquidity and valuation.

Base CaseCentral scenario

$2.2055%

In the base case, Propanc successfully completes its manufacturing milestones (preproduction in August, engineering run in October, and GMP production in December 2026) and files its Clinical Trial Application (CTA) in Australia. The stock remains highly volatile as the company continues to draw down capital from its financing facility to fund operations, resulting in moderate dilution. Nasdaq compliance is maintained post-reverse split, but the stock trades near its current levels until clinical data emerges.

Bull CaseUpside scenario

$5.0025%

The bull case relies on the successful initiation and positive safety/tolerability data from the Phase 1b trial of PRP in advanced solid tumors. If PRP demonstrates a favorable safety profile and early signs of efficacy, it could validate the company's proenzyme therapy platform. Furthermore, efficient drawdowns from the $100 million private placement facility without excessive dilution, combined with the execution of the $5.0 million share buyback program, could significantly boost investor confidence and drive valuation recovery.

Scenarios reflect our research view at the research date.

Key Investment Merits

Lead asset PRP holds US FDA Orphan Drug Designation for pancreatic cancer, providing 7 years of market exclusivity post-approval.
Preclinical data demonstrates over 85% tumor growth inhibition, targeting cancer stem cells to prevent recurrence and metastasis.
Established GMP manufacturing partnership with a European CDMO and pharmacokinetics assay validation with FyoniBio GmbH.
Access to a private placement facility of up to $100 million to fund clinical development.

Key Investment Risks

Extremely limited cash reserves ($443,702 as of March 31, 2026) relative to high clinical development costs.
High reliance on dilutive equity financing and private placements to sustain operations.
History of persistent net losses ($6.36 million for Q3 ended March 31, 2026) and accumulated deficit of $140.84 million.
Risk of delisting from Nasdaq if the stock fails to maintain the minimum bid price requirement post-reverse split.

Thesis Invalidation Triggers

Failure to initiate the Phase 1b clinical trial of PRP by the end of 2026.
Inability to access further tranches of the Series C financing facility, leading to a severe liquidity crisis.
Delisting of PPCB common stock from the Nasdaq Capital Market.
Unfavorable safety or toxicity signals emerging during the Phase 1b trial.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.